Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.63 |
| ▸ | JAK2 | O60674 | 4/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | AKT2 | P31751 | 1/20 | 0.54 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277773 | 0.84 | JAK3 (0.66) | JAK3JAK2KITAKT1HTR2C | |
| SCHEMBL10156821 | 0.83 | JAK3 (0.59) | JAK3KITAKT1HTR2CROCK2 | |
| SCHEMBL2780797 | 0.83 | AKT2 (0.67) | JAK3AKT1ROCK2AKT2AKT3 | |
| SCHEMBL13510875 | 0.82 | KIT (0.64) | JAK3KITAKT1ROCK2AKT2 | |
| SCHEMBL323706 | 0.82 | JAK3 (0.78) | JAK3JAK2LCKJAK1TYK2 | |
| SCHEMBL2778598 | 0.80 | AKT1 (0.63) | JAK3KITAKT1HTR2CROCK2 | |
| SCHEMBL15827640 | 0.80 | JAK3 (0.58) | JAK3KITAKT1HTR2CROCK2 | |
| SCHEMBL392634 | 0.79 | AKT1 (0.77) | AKT1ROCK2AKT2AKT3 | |
| SCHEMBL3490979 | 0.79 | AKT2 (0.62) | JAK3JAK2AKT1ROCK2AKT2 | |
| SCHEMBL392635 | 0.79 | AKT1 (0.77) | AKT1ROCK2AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| EP-2029592-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007125325-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | JAK3 62/4885JAK2 77/4885KIT 1632/4885 |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | JAK3 309/4885JAK2 66/4885KIT 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.